FUNDACIó INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS - Spain 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2016-01-01 - 2022-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 15
As coordinator: 2
As participant: 7
Sole participant: 6
Coordinator / Participant Ratio: 0.29*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 7.542.464 4.014.435 2.079.267 4 1
2020 172.932 8.776.425 373.332 1 2
2019 308.122 3.999.601 459.372 2 1
2018 158.122 0 158.122 1
2017 0 20.200.000 153.348 1
2016 0 5.825.128 2.495.746 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
MLL MUNCHNER LEUKAMIELABOR3
STICHTING VUMC3
UNIVERSITY OF CAMBRIDGE3
UNIVERSITY OF HELSINKI3
UNIVERSITY OF NEWCASTLE UPON TYNE3
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS2
BIOBAM BIOINFORMATICS SL2
BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE2
CELGENE MANAGEMENT SARL2
CHARITE UNIVERSITAETSMEDIZIN BERLIN2
EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION2
EUROPEAN HEMATOLOGY ASSOCIATION2
EUROPEAN RESEARCH INITIATIVE ON CLL EV2
FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS2
FUNDACION HOSPITAL LA FE2
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON2
GENOME RESEARCH2
GMV SOLUCIONES GLOBALES INTERNET SAU2
GPOH GEMEINNUTZIGE2
GROUPE FRANCOPHONE DES MYELODYSPLASIES2
LEUKANET EV2
MASARYKOVA UNIVERZITA2
MEDISAPIENS OY2
MENARINI RICERCHE2
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE2
NESTEC2
NOVARTIS PHARMA2
OSPEDALE PEDIATRICO BAMBINO GESU2
STIFTUNG ELN FOUNDATION2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
THE LYMPHOMA STUDY ASSOCIATION2
UNIVERSIDAD DE NAVARRA2
UNIVERSITA DEGLI STUDI DI TORINO2
UNIVERSITAET ULM2
UNIVERSITY OF BOLOGNA2
VIB VZW2
4 SC1
4SC DISCOVERY1
ABBVIE INC1
AMGEN1
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS1
ASSERTA GLOBAL HEALTHCARE SOLUTIONS1
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1
ASSOCIAZIONE HAND IN HAND1
BARTS AND THE LONDON NHS TRUST1
BAYER1
BAYER PHARMA1
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG1
CHARLES UNIVERSITY PRAGUE1
CHROMACURE1
CHRONOS THERAPEUTICS LIMITED1
CLICLAB TRANSFORMATIVE AGENT SL1
CLINICA MEDITERRANEA1
CONSIGLIO NAZIONALE DELLE RICERCHE1
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER1
EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL1
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL1
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH1
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE1
FUNDACIO INSTITUT DE RECERCA BIOMEDICA1
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON1
FUNDACION MARIA CECILIA DE AYUDA AL NINO ONCOLOGICO1
FUNDACION NATALI DAFNE FLEXER1
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA1
FUNDACION PEREZ SCREMINI1
GEORG SPEYER HAUS CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT1
GROUP FOR RESEARCH ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA1
HEINRICHHEINEUNIVERSITAET DUESSELDORF1
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT1
HOSPITAL DE PEDIATRIA SAMIC PROF DR JUAN P GARRAHAN1
HOSPITAL SANT JOAN DE DEU1
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE1
INTOMICS AS1
ISTITUTO NAZIONALE DI FISICA NUCLEARE1
ISTITUTO SUPERIORE DI SANITA1
JANSSEN PHARMACEUTICA NV1
JENACELL1
JOHANN WOLFGANG GOETHEUNIVERSITATFRANKFURT AM MAIN1
KAROLINSKA INSTITUTET1
KITHER BIOTECH1
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN1
LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN1
LYSARC1
MAXPLANCKGESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV1
MEDIZINISCHE UNIVERSITAET WIEN1
PERCUROS BV1
PFIZER LIMITED1
PROGREDUM1
PULSERAS CANDELA1
QUANTITATIVE GENOMIC MEDICINE LABORATORIES SL1
RHEINISCHE FRIEDRICH WILHELMS UNIVERSITAET BONN1
SERVICIO DE SALUD METROPOLITANO NORTE1
ST ANNA KINDERKREBSFORSCHUNG VEREIN1
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM1
TACIT BIO INNOVATION LIMITED1
TAKEDA DEVELOPMENT CENTRE EUROPE1
TECOBIOSCIENCES1

Constancy:

Total number of partners: 167
Partner loyalty:
Frequent Partner: (> 2 projects): 26
Rare Partner: 141
Frequent / Rare Partner Ratio: 0.18

Project overview:

Start dateProjectacronymrolefundingpartners
2021-09-01Senescence as a key factor in leukemogenesis and bone marrow homeostasis in aging SENAGEcoordinator172.9321
2021-07-01PI3K/PTEN-related monogenic disease to understand cancer PIPgencoordinator4.099.07511
2021-03-01Deconstructing the evolution of metastasis Evometparticipant4.014.43515
2021-01-01Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells. INTERCEPT-MDScoordinator3.120.45610
2021-01-01Clinical translation of a novel CD1a-directed CAR for relapse/refractory cortical T-cell Acute Lymphoblastic Leukemia: feasibility, efficacy and safety IT4-TALLcoordinator150.0001
2020-12-01Mechanisms of Sirtuin-dependent regulation of immunity and leukemogenesis SirT-IMLEUcoordinator172.9321
2020-10-01HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS HARMONY PLUSparticipant6.715.62541
2020-05-01DevelOpmeNt of Cancer RNA TherapEutics cONCReTEparticipant2.060.80017
2019-01-01Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia IT4B-ALLcoordinator150.0001
2019-01-01Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse HifLICscoordinator158.1221
2019-01-01Childhood Leukemia: Overcoming distance between South America and Europe Regions CLOSERparticipant3.999.60114
2018-04-01Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia InTheMLLrBALLcoordinator158.1221
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-03-01Chromatin and Metabolism Chromatin-metabolism interactions as targets for healthy living ChroMeparticipant3.825.12814
2016-01-01GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OFINFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA INFANTLEUKEMIAparticipant2.000.0001